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Background
In 1995 our institution developed a protocol to treat chil-
dren with pamidronate. Several protocols have been pub-
lished to treat osteogenesis imperfecta (OI) in the last
decades. Objectives: to review the usefulness of our proto-
col in OI and to compare it with published protocols.
Materials and methods
Retrospective review of OI patients treated with pamidro-
nate from 1995 to 2006 in our centre. Inclusion criteria:
OI < 18 years with z-score < -2.5, fractures and z < -1 or
documented bone pain with z < -1. Treatment: 60 mg or
30 mg (in prepubescents) of pamidronate every six
months in a single dose.
Results
20 patients included, average length of treatment 4.1 years
(range: 18 months – 8 years). Average Z-score increased
from -4.3 to -2.9 after treatment and fracture rate
decreased. Table 1 shows the comparison between our
protocol and the ones published by Glorieux [1] and
Arikoski [2].
Conclusion
Despite a lower increase in z-score in our serie, the clinical
efficacy is similar to other protocols. There is a tendency
towards greater gain in Z-score as the annual dosage
increases.
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Table 1: Comparison between our protocol and the ones published by Glorieux and Arikoski
HSJD Glorieux [1] Arikoski [2]
Patients 20 30 12
Dose (mg/Kg/year) 2.4(0.3) 6.8(1.1) 12
Periodicity of infusions (m) 6 3–4 3
Basal z-score -4.3(2) -5.3(1.2) *
Final z-score -3.38(2.4) ** -3.4(1.5) *
Years of treatment 3** 2.1(range 1.3–5) 1
Mean annual increase in: z-score BMD 0.49 (0.1) 21.1 (5.1) 0.95 41.9 (29) * 63.5(37.3)
Mean(SD). m: months. *Data not available. ** For comparability with the other series only the results of the first 3 years are shown.